Platform

RareScan

Around 350 million people suffer from rare diseases, yet only 5% have approved treatments. Diagnoses are often complicated by variants of uncertain significance (VUS). Constantiam Biosciences’ RareScan™ platform uses Deep Mutational Scanning (DMS) to classify VUS and predict drug responses, improving patient access to treatments and aiding drug development for rare diseases.

Genable

Genable™ revolutionizes drug target discovery by using human genetic data, massively-multiplexed experiments, and machine learning to prioritize high-confidence targets. This accelerates discovery, increases success rates, and reduces costs, offering a major advantage over traditional methods in developing precision diagnostics and therapies.

StratiVar

StratiVar optimizes clinical trials enrollment by proactively assessing the susceptibility of all single amino acid variations of a targeted protein to a novel therapeutic. These assessments are derived from drug-specific Deep Mutational Scans (DMS), centered on verified human data controls, and are translated into actionable insights including drug-sensitivity profile and predicted probabilities of patient response for clinical trial designers and physicians.

MAVEvidence

MAVEvidence is the premier functional evidence resource for the clinical genetics community. MAVEvidence delivers increased productivity and time savings through comprehensive curation, rigorous analysis, and clear presentation of functional evidence derived from high-throughput studies of genetic variants.